Validation of pharmacodynamic assays to evaluate the clinical efficacy of an antisense compound (AEG 35156) targeted to the X-linked inhibitor of apoptosis protein XIAP

The inhibitor of apoptosis protein, XIAP, is frequently overexpressed in chemoresistant human tumours. An antisense oligonucleotide (AEG 35156/GEM 640) that targets XIAP has recently entered phase I trials in the UK. Method validation data are presented on three pharmacodynamic assays that will be u...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Cummings, J, Ward, T H, LaCasse, E, Lefebvre, C, St-Jean, M, Durkin, J, Ranson, M, Dive, C
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Nature Publishing Group 2005
Pynciau:
Translational Therapeutics
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC2362094/
https://ncbi.nlm.nih.gov/pubmed/15685240
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6602363
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg